Semaglutide 2.4 mg Improves Liver Histology in MASH

The ESSENCE interim analysis provides the first large phase 3 histologic evidence that once-weekly semaglutide resolves steatohepatitis and reduces fibrosis in patients with moderate to advanced MASH.

semaglutideGLP-1 receptor agonistmetabolic dysfunction-associated steatohepatitisMASHNASHliver fibrosisobesitytype 2 diabetesphase 3 trialESSENCEhepatology Endocrinology / Obesity

Background Information

Semaglutide shows promise in treating metabolic dysfunction-associated steatohepatitis.

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition with limited treatment options, and improving liver histology could have significant health benefits. Semaglutide 2.4 mg resolved steatohepatitis in 62.9% of patients compared to 34.3% with placebo and reduced liver fibrosis in 36.8% compared to 22.4% with placebo. While semaglutide shows promise for treating MASH, gastrointestinal side effects must be considered and long-term outcomes remain to be fully evaluated. Semaglutide 2.4 mg significantly improves MASH outcomes with manageable side effects.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V, ESSENCE Study Group

Citation: Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. The New England journal of medicine. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2413258

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →